Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of VTX958 in active psoriatic arthritis
2022-003056-14Phase 2Terminated
- Sponsor
- Ventyx Biosciences
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriatic arthritis (PsA) comparing VTX958 with Placebo (2 arms). Primary endpoint: ACR20 response at Week 16. Started Dec 2022; status: terminated.
02
Drugs
cenacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2022-003056-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003056-14.